Longview Acquisition Corp. II (NYSE:LGV – Get Rating) and SANUWAVE Health (OTCMKTS:SNWV – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.

Risk and Volatility

Longview Acquisition Corp. II has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500. Comparatively, SANUWAVE Health has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Longview Acquisition Corp. II and SANUWAVE Health, as provided by MarketBeat.

Valuation and Earnings

This table compares Longview Acquisition Corp. II and SANUWAVE Health's top-line revenue, earnings per share (EPS) and valuation.

Longview Acquisition Corp. II has higher earnings, but lower revenue than SANUWAVE Health.

Institutional and Insider Ownership

66.3% of Longview Acquisition Corp. II shares are owned by institutional investors. 26.4% of Longview Acquisition Corp. II shares are owned by insiders. Comparatively, 16.4% of SANUWAVE Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Longview Acquisition Corp. II and SANUWAVE Health's net margins, return on equity and return on assets.

Summary

Longview Acquisition Corp. II beats SANUWAVE Health on 5 of the 8 factors compared between the two stocks.

About Longview Acquisition Corp. II

(Get Rating)

Longview Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on businesses in the healthcare, industrials, consumer, media, technology, and technology services sector. The company was incorporated in 2020 and is based in New York, New York.

About SANUWAVE Health

(Get Rating)

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

Receive News & Ratings for Longview Acquisition Corp. II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longview Acquisition Corp. II and related companies with MarketBeat.com's FREE daily email newsletter.